CN116056693A - β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途 - Google Patents

β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途 Download PDF

Info

Publication number
CN116056693A
CN116056693A CN202180048775.4A CN202180048775A CN116056693A CN 116056693 A CN116056693 A CN 116056693A CN 202180048775 A CN202180048775 A CN 202180048775A CN 116056693 A CN116056693 A CN 116056693A
Authority
CN
China
Prior art keywords
beta
growth factor
epidermal growth
adrenergic receptor
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180048775.4A
Other languages
English (en)
Inventor
卢俊玮
苏中慧
柯毓贤
钟文宏
陈美均
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chang Gung University CGU
Chang Gung Memorial Hospital
Original Assignee
Chang Gung University CGU
Chang Gung Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chang Gung University CGU, Chang Gung Memorial Hospital filed Critical Chang Gung University CGU
Publication of CN116056693A publication Critical patent/CN116056693A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种β‑1肾上腺素受体拮抗剂用于制备减少或预防表皮生长因子受体抑制剂诱导的正常上皮细胞损伤以及抑制癌细胞的组合物的用途，通过施用包含β‑1肾上腺素受体拮抗剂的组合物以减少表皮生长因子受体抑制剂所诱导的正常上皮细胞损伤，并可与表皮生长因子受体抑制剂一同施用以协同作用抑制癌细胞。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN202180048775.4A 2020-07-10 2021-07-08 β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途 Pending CN116056693A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050390P 2020-07-10 2020-07-10
US63/050,390 2020-07-10
PCT/CN2021/105167 WO2022007878A1 (zh) 2020-07-10 2021-07-08 β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途

Publications (1)

Publication Number Publication Date
CN116056693A true CN116056693A (zh) 2023-05-02

Family

ID=79552282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048775.4A Pending CN116056693A (zh) 2020-07-10 2021-07-08 β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途

Country Status (6)

Country Link
US (1) US20230248671A1 (zh)
EP (1) EP4180033A1 (zh)
JP (1) JP2023533911A (zh)
CN (1) CN116056693A (zh)
TW (2) TWI813331B (zh)
WO (1) WO2022007878A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275978A1 (en) * 2004-02-20 2007-11-29 Galderma Research & Development S.N.C. Of at Use of an Antagonist Compound of at Least One Receptor Selected From a Group Comprising Beta-Adrenergic Receptors, A at1, 5-Ht5 and Galanin Receptor for Preparing a Pharmaceutical Composition for Treating Rosacea
US20110190244A1 (en) * 2010-02-01 2011-08-04 Peter Maccallum Cancer Institute Method of treatment of egfr inhibitor toxicity
US20120178757A1 (en) * 2010-12-09 2012-07-12 Nottingham University Hospitals Nhs Trust Method For The Prevention Of Cancer Metastasis
CN105263482A (zh) * 2013-04-05 2016-01-20 努梅迪公司 胃肠病症和其他病症的治疗
US20160175485A1 (en) * 2013-08-27 2016-06-23 The Regents Of The University Of California Combination therapy to promote wound healing
KR20160124012A (ko) * 2015-04-16 2016-10-26 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
US20200206164A1 (en) * 2018-12-28 2020-07-02 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7081482B2 (en) * 1999-11-30 2006-07-25 Alcon, Inc. Use of β-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
CN102886045A (zh) * 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
US8686051B2 (en) * 2007-01-29 2014-04-01 Vlife Sciences Technologies Pvt. Ltd. Pharmaceutical composition for treatment of diabetic complications
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
MX2015001194A (es) * 2012-07-27 2015-11-23 Izumi Technology Llc Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas.
EP3463344A4 (en) * 2016-06-01 2020-02-12 Harold Richard Hellstrom TREATMENT OF DRY EYE WITH PARASYMPATHIC AND ANTISYMPATHIC AGENTS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275978A1 (en) * 2004-02-20 2007-11-29 Galderma Research & Development S.N.C. Of at Use of an Antagonist Compound of at Least One Receptor Selected From a Group Comprising Beta-Adrenergic Receptors, A at1, 5-Ht5 and Galanin Receptor for Preparing a Pharmaceutical Composition for Treating Rosacea
US20110190244A1 (en) * 2010-02-01 2011-08-04 Peter Maccallum Cancer Institute Method of treatment of egfr inhibitor toxicity
US20120178757A1 (en) * 2010-12-09 2012-07-12 Nottingham University Hospitals Nhs Trust Method For The Prevention Of Cancer Metastasis
CN105263482A (zh) * 2013-04-05 2016-01-20 努梅迪公司 胃肠病症和其他病症的治疗
US20160175485A1 (en) * 2013-08-27 2016-06-23 The Regents Of The University Of California Combination therapy to promote wound healing
KR20160124012A (ko) * 2015-04-16 2016-10-26 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
US20200206164A1 (en) * 2018-12-28 2020-07-02 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
余元勋: "中国分子肺癌学", 31 August 2015, 安徽科学技术出版社 *
彭黎明: "细胞凋亡的基础与临床", 31 July 2000, 人民卫生出版社 *

Also Published As

Publication number Publication date
EP4180033A1 (en) 2023-05-17
WO2022007878A1 (zh) 2022-01-13
US20230248671A1 (en) 2023-08-10
TWI813331B (zh) 2023-08-21
TW202237123A (zh) 2022-10-01
TW202202144A (zh) 2022-01-16
TWI776584B (zh) 2022-09-01
JP2023533911A (ja) 2023-08-07

Similar Documents

Publication Publication Date Title
AU2013402794B2 (en) Cancer treatment with combination of plinabulin and taxane
Ryu et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901
CN110339159A (zh) 脂肪组织的减少
JP2012136535A (ja) 癌治療のためのｒｈｕＭＡｂＨＥＲ２と組み合わせたドセタキセル
CN101909633A (zh) γ-分泌酶抑制剂用于治疗癌症的应用
US20110081359A1 (en) Alpha 5 beta 1 and its ability to regulate the cell survival pathway
WO2022012329A1 (zh) 一种在肿瘤治疗中具有增效作用的化合物的应用
KR20210013155A (ko) 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
CN110755431B (zh) 地氯雷他定在制备抗肝癌药物中的应用
WO2024120523A1 (zh) 一种治疗前列腺癌的药物组合及其应用
US20220265760A1 (en) Leuprolide acetate compositions and methods of using the same to treat breast cancer
EP4098251A1 (en) Use of mitoxantrone hydrochloride liposome for treating breast cancer
CN116056693A (zh) β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途
WO2019034069A1 (zh) 一种抗肿瘤联合用药物及其在制备抗癌药物中的用途
CN109876000A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
EP3565547B1 (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
Wuerstlein et al. Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia)
AU2013351180A1 (en) Combination therapy with volasertib
TWI607751B (zh) Statin compounds for the treatment of gastric cancer
WO2017011973A1 (zh) 他汀类化合物用于治疗胃癌的用途
CN112587518B (zh) 鸦胆子苦醇药物组合物及其用途
Feldstein et al. The Effect of Preemptive Local Anesthesia on Postoperative Pain Following Vaginal Hysterectomy: A Randomized Controlled Trial
KR20240108407A (ko) 총상 신경섬유종의 치료 또는 예방에 사용하기 위한 니트록솔린
CA3199466A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination